SEC Comment Letter for Protara Therapeutics, Inc. (TARA) (CIK 0001359931) (TARA) — Jan 30, 2019
Protara Therapeutics, Inc. (TARA) (CIK 0001359931)
Date: Jan. 30, 2019 · CIK: 0001359931 · Accession: 0000000000-19-000415
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-228865
Letter
January 30, 2019 Timothy P. Noyes Chief Executive Officer Proteon Therapeutics, Inc. 200 West Street Waltham, MA 02451 Re:Proteon Therapeutics, Inc. Registration Statement on Form S-3 Filed December 18, 2018 File No. 333-228865 Dear Mr. Noyes: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Donald Field at 202-551-3680 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
January 30, 2019
Timothy P. Noyes
Chief Executive Officer
Proteon Therapeutics, Inc.
200 West Street
Waltham, MA 02451
Re:Proteon Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 18, 2018
File No. 333-228865
Dear Mr. Noyes:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Donald Field at 202-551-3680 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance